Oral bisphosphonates and upper gastrointestinal tract problems: What is the evidence?

Mayo Clinic Proceedings

Volumn 77, Issue 10, 2002, Pages 1031-1043

  Cryer, Byron ^a   Bauer, Douglas C ^b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; ETIDRONIC ACID; HISTAMINE H2 RECEPTOR ANTAGONIST; INDOMETACIN; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PAMIDRONIC ACID; PLACEBO; PROTON PUMP INHIBITOR; RISEDRONIC ACID; TILUDRONIC ACID;

ADULT; AGED; ANIMAL CELL; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG INDUCED DISEASE; DRUG SAFETY; ESOPHAGITIS; EVIDENCE BASED MEDICINE; FEMALE; GASTROINTESTINAL ENDOSCOPY; GASTROINTESTINAL TOXICITY; HUMAN; MAJOR CLINICAL STUDY; MALE; NONHUMAN; OSTEOPOROSIS; POSTMENOPAUSE OSTEOPOROSIS; RANDOMIZED CONTROLLED TRIAL; RAT; SINGLE BLIND PROCEDURE; TREATMENT OUTCOME;

EID: 0036789682     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.4065/77.10.1031     Document Type: Article

References (86)

1. Tonino RP, Meunier PJ, Emkey R, et al. Phase III Osteoporosis Treatment Study Group. Skeletal benefits of alendronate: 7-year treatment of postmenopausal osteoporotic women. J Clin Endocrinol Metab. 2000;85:3109-3115.
2. Hochberg M. Preventing fractures in postmenopausal women with osteoporosis: a review of recent controlled trials of antiresorptive agents. Drugs Aging. 2000;17:317-330.
3. McClung MR. Bisphosphonates in osteoporosis: recent clinical experience. Expert Opin Pharmacother. 2000;1:225-238.
4. Watts N, Freedholm D, Daifotis A. The clinical tolerability profile of alendronate. Int J Clin Pract Suppl. 1999;101:51-61.
5. Jeal W, Barradell LB, McTavish D. Alendronate: a review of its pharmacological properties and therapeutic efficacy in postmenopausal osteoporosis. Drugs. 1997;53:415-434.
6. Bauer DC, Black D, Ensrud K, et al. Upper gastrointestinal tract safety profile of alendronate: the Fracture Intervention Trial. Arch Intern Med. 2000;160:517-525.
7. Delaney MF, Shaw J, Hurwitz S, LeBoff MS. Bone density changes in response to risedronate once weekly [abstract]. Endocr Soc Meet Proc Program Abstr. 2001;83:249. Abstract P1-469.
8. Siris ES, Chines AA, Altman RD, et al. Risedronate in the treatment of Paget's disease of bone: an open label, multicenter study. J Bone Miner Res. 1998;13:1032-1038.
9. Lufkin EG, Argueta R, Whitaker MD, et al. Pamidronate: a unrecognized problem in gastrointestinal tolerability. Osteoporos Int. 1994;4:320-322.
10. Siris E, Weinstein RS, Altman R, et al. Comparative study of alendronate versus etidronate for the treatment of Paget's disease of bone. J Clin Endocrinol Metab. 1996;81:961-967.
11. Roux C, Gennari C, Farrerons J, et al. Comparative prospective, double-blind, multicenter study of the efficacy of tiludronate and etidronate in the treatment of Paget's disease of bone. Arthritis Rheum. 1995;38:851-858.
12. Plosker GL, Goa KL. Clodronate: a review of its pharmacological properties and therapeutic efficacy in resorptive bone disease. Drugs. 1994;47:945-982.
13. Guyatt GH. Evidence-based management of patients with osteoporosis. J Clin Densitom. Spring 1998;1:395-402.
14. Seeman E. Osteoporosis: trials and tribulations. Am J Med. 1997;103(suppl 2A):74S-87S.
15. Torgerson DJ, Roberts C. Understanding controlled trials: randomisation methods: concealment. BMJ. 1999;319:375-376.
16. Cummings SR, Chapurlat RD. What PROOF proves about calcitonin and clinical trials [editorial]. Am J Med. 2000;109:330-331.
17. Bone HG, Adami S, Rizzoli R, et al. Weekly administration of alendronate: rationale and plan for clinical assessment. Clin Ther. 2000;22:15-28.
18. Peter CP, Handt LK, Smith SM. Esophageal irritation due to alendronate sodium tablets: possible mechanisms. Dig Dis Sci. 1998;43:1998-2002.
19. Halasy-Nagy JM, Rodan GA, Reszka AA. Keratinocyte model for bisphosphonate esophageal irritation: inhibition of cell growth by combined inhibition of protein prenylation and sterol synthesis. J Bone Miner Res. 1999;14(suppl 1):S406. Abstract SA387.
20. Karam SM. Lineage commitment and maturation of epithelial cells in the gut. Front Biosci. 1999;4:D286-D298.
21. Reszka AA, Halasy-Nagy J, Rodan GA. Nitrogen-bisphosphonates block retinoblastoma phosphorylation and cell growth by inhibiting the cholesterol biosynthetic pathway in a keratinocyte model for esophageal irritation. Mol Pharmacol. 2001;59:193-202.
22. Suri S, Monkkonen J, Taskinen M, et al. Nitrogen-containing bisphosphonates induce apoptosis of Caco-2 cells in vitro by inhibiting the mevalonate pathway: a model of bisphosphonate-induced gastrointestinal toxicity. Bone. 2001;29:336-343.
23. Lichtenberger LM, Romero JJ, Gibson GW, Blank MA. Effect of bisphosphonates on surface hydrophobicity and phosphatidylcholine concentration of rodent gastric mucosa. Dig Dis Sci. 2000;45:1792-1801.
24. Blank MA, Ems BL, Gibson GW, et al. Nonclinical model for assessing gastric effects of bisphosphonates. Dig Dis Sci. 1997;42:281-288.
25. Elliott SN, McKnight W, Davies NM, MacNaughton WK, Wallace JL. Alendronate induces gastric injury and delays ulcer healing in rodents. Life Sci. 1998;62:77-91.
26. Peter CP, Kindt MV, Majka JA. Comparative study of potential for bisphosphonates to damage gastric mucosa of rats. Dig Dis Sci. 1998;43:1009-1015.
27. Talley NJ, O'Keefe EA, Zinsmeister AR, Melton LJ III. Prevalence of gastrointestinal symptoms in the elderly: a population-based study. Gastroenterology. 1992;102:895-901.
28. Locke GR III, Talley NJ, Fett SL, Zinsmeister AR, Melton LJ III. Prevalence and clinical spectrum of gastroesophageal reflux: a population-based study in Olmsted County, Minnesota. Gastroenterology. 1997;112:1448-1456.
29. van Staa T, Abenhaim L, Cooper C. Upper gastrointestinal adverse events and cyclical etidronate. Am J Med. 1997;103:462-467.
30. Donahue JG, Chan KA, Andrade SE, et al. Gastric and duodenal safety of daily alendronate. Arch Intern Med. 2002;162:936-942.
31. Lowe CE, Depew WT, Vanner SJ, Paterson WG, Meddings JB. Upper gastrointestinal toxicity of alendronate. Am J Gastroenterol. 2000;95:634-640.
32. Lanza F, Schwartz H, Sahba B, et al. An endoscopic comparison of the effects of alendronate and risedronate on upper gastrointestinal mucosae. Am J Gastroenterol. 2000;95:3112-3117.
33. Lanza F, Rack MF, Simon TJ, Lombardi A, Reyes R, Suryawanshi S. Effects of alendronate on gastric and duodenal mucosa. Am J Gastroenterol. 1998;93:753-757.
34. Lanza F, Sahba B, Schwartz H, et al. The upper GI safety and tolerability of oral alendronate at a dose of 70 milligrams once weekly: a placebo-controlled endoscopy study. Am J Gastroenterol. 2002;97:58-64.
35. Graham DY, Malaty HM. Alendronate and naproxen are synergistic for development of gastric ulcers [published correction appears in Arch Intern Med. 2001;161:1862]. Arch Intern Med. 2001;161:107-110.
36. Lanza FL, Hunt RH, Thompson AB, Provenza JM, Blank MA. Endoscopic comparison of esophageal and gastroduodenal effects of risedronate and alendronate in postmenopausal women. Gastroenterology. 2000;119:631-638.
37. Thomson ABR, Marshall JK, Hunt RH, Lanza FL, Blank MA. Follow-up endoscopy study comparing risedronate and alendronate in postmenopausal women stratified by H. pylori status [abstract]. Bone. 2001;28(suppl):S222.
38. Graham DY, Malaty HM. Alendronate gastric ulcers. Aliment Pharmacol Ther. 1999;13:515-519.
39. Marshall JK, Rainsford KD, James C, Hunt RH. A randomized controlled trial to assess alendronate-associated injury of the upper gastrointestinal tract. Aliment Pharmacol Ther. 2000;14:1451-1457.
40. Graham DY, Malaty HM, Goodgame R. Primary amino-bisphosphonates: a new class of gastrotoxic drugs-comparison of alendronate and aspirin. Am J Gastroenterol. 1997;92:1322-1325.
41. Lanza FL, Rack MF, Li Z, Krajewski SA, Blank MA. Placebo-controlled, randomized, evaluator-blinded endoscopy study of risedronate vs. aspirin in healthy postmenopausal women. Aliment Pharmacol Ther. 2000;14:1663-1670.
42. Harris ST, Watts NB, Genant HK, et al. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. JAMA. 1999;282:1344-1352.
43. Reginster J, Minne HW, Sorensen OH, et al. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Osteoporos Int. 2000;11:83-91.
44. McClung MR, Geusens P, Miller PD, et al. Hip Intervention Program Study Group. Effect of risedronate on the risk of hip fracture in elderly women. N Engl J Med. 2001;344;333-340.
45. Pols HA, Felsenberg D, Hanley DA, et al. Foxamax International Trial Study Group. Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study. Osteoporos Int. 1999;9:461-468.
46. Hosking D, Chilvers CE, Christiansen C, et al. Early Postmenopausal Intervention Cohort Study Group. Prevention of bone loss with alendronate in postmenopausal women under 60 years of age. N Engl J Med. 1998;338:485-492.
47. Liberman UA, Weiss SR, Broll J, et al. Alendronate Phase III Osteoporosis Treatment Study Group. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med. 1995;333:1437-1443.
48. Black DM, Cummings SR, Karpf DB, et al. Fracture Intervention Trial Research Group. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet. 1996;348:1535-1541.
49. Cummings SR, Black DM, Thompson DE, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA. 1998;280:2077-2082.
50. McClung M. Results of special studies with alendronate. Int J Clin Pract Suppl. 1999;101:67-72.
51. McClung M, Clemmesen B, Daifotis A, et al. Alendronate Osteoporosis Prevention Study Group. Alendronate prevents postmenopausal bone loss in women without osteoporosis: a double-blind, randomized, controlled trial. Ann Intern Med. 1998;128:253-261.
52. Orwoll E, Ettinger M, Weiss S, et al. Alendronate for the treatment of osteoporosis in men. N Engl J Med. 2000;343:604-610.
53. Saag KG, Emkey R, Schnitzer TJ, et al. Glucocorticoid-Induced Osteoporosis Intervention Study Group. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. N Engl J Med. 1998;339:292-299.
54. Adachi JD, Saag KG, Delmas PD, et al. Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial. Arthritis Rheum. 2001;44:202-211.
55. Lindsay R, Cosman F, Lobo RA, et al. Addition of alendronate to ongoing hormone replacement therapy in the treatment of osteoporosis: a randomized, controlled clinical trial. J Clin Endocrinol Metab. 1999;84:3076-3081.
56. Bone HG, Greenspan SL, McKeever C, et al. Alendronate/Estrogen Study Group. Alendronate and estrogen effects in postmenopausal women with low bone mineral density. J Clin Endocrinol Metab. 2000;85:720-726.
57. Reid IR, Siris E. Alendronate in the treatment of Paget's disease of bone. Int J Clin Pract Suppl. 1999;101:62-66.
58. Schnitzer T, Bone HG, Crepaldi G, et al. Alendronate Once-Weekly Study Group. Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Aging (Milano). 2000;12:1-12.
59. Genco RJ, Van Dyke T, Leung A, et al. Two-year gastrointestinal safety and tolerability of alendronate 70mg once weekly [abstract]. J Bone Miner Res. 2001;16(suppl 1):S528. Abstract M404.
60. Greenspan SL, Field-Munves EM, Tonino RP, et al. Alendronate 70 mg once weekly vs. placebo: tolerability study in patients with osteoporosis [abstract]. J Bone Miner Res. 2001;16(suppl 1):S405. Abstract SU403.
61. Genco R, Adams D, Jeffcoat M, et al. Safety and tolerability of once-weekly alendronate 70 mg is comparable to that of placebo in men and women with periodontal disease [abstract]. J Bone Miner Res. 2000;15(suppl 1):S489. Abstract M131.
62. Palmisano J, Lewiecki EM, Rosen C, et al. Alendronate 70 mg once weekly and alendronate 10 mg once daily preference study in postmenopausal women with osteoporosis [abstract]. J Bone Miner Res. 2001;16(suppl 1):S404. Abstract SU396.
63. Brown JP, Singer FR, Siris ES, et al. A safety review of the use of risedronate in the treatment of Paget's disease of bone [abstract]. J Rheumatol Suppl. 1998;52:53. Abstract T80.
64. Actonel [prescribing information]. Kansas City, Mo: Aventis Pharmaceuticals, Inc; 2000.
65. Cohen S, Levy RM, Keller M, et al. Risedronate therapy prevents corticosteroid-induced bone loss: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum. 1999;42:2309-2318.
66. Wallach S, Cohen S, Reid DM, et al. Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy. Calcif Tissue Int. 2000;67:277-285.
67. Reid DM, Hughes RA, Laan RF, et al, European Corticosteroid-Induced Osteoporosis Treatment Study. Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial. J Bone Miner Res. 2000;15:1006-1013.
68. Eastell R, Devogelaer JP, Peel NF, et al. Prevention of bone loss with risedronate in glucocorticoid-treated rheumatoid arthritis patients. Osteoporos Int. 2000;11:331-337.
69. Dunn CJ, Goa KL. Risedronate: a review of its pharmacological properties and clinical use in resorptive bone disease. Drugs. 2001;61:685-712.
70. Fogelman I, Moreland L, Woodson G, et al. Gastrointestinal side effects and endoscopic findings similar between risedronate and placebo-treated patients [abstract]. Osteoporos Int. 2000;11(suppl 2):S179. Abstract 459 (423).
71. Taggart H, Bolognese MA, Lindsay R, et al. Upper gastrointestinal tract safety of risedronate: a pooled analysis of 9 clinical trials. Mayo Clin Proc. 2002;77:262-270.
72. Reid IR, Wattie DJ, Evans MC, Gamble GD, Stapleton JP, Cornish J. Continuous therapy with pamidronate, a potent bisphosphonate, in postmenopausal osteoporosis. J Clin Endocrinol Metab. 1994;79:1595-1599.
73. Harris ST, Watts NB, Jackson RD, et al. Four-year study of intermittent cyclic etidronate treatment of postmenopausal osteoporosis: three years of blinded therapy followed by one year of open therapy. Am J Med. 1993;95:557-567.
74. Adachi JD, Bensen WG, Brown J, et al. Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis. N Engl J Med. 1997;337:382-387.
75. Reginster JY, Christiansen C, Roux C, Fechtenbaum J, Rouillon A, Tou KP. Intermittent cyclic tiludronate in the treatment of osteoporosis. Osteoporos Int. 2001;12:169-177.
76. McCloskey E, Selby P, de Takats D, et al. Effects of clodronate on vertebral fracture risk in osteoporosis: a 1-year interim analysis. Bone. 2001;28:310-315.
77. Giannini S, D'angelo A, Malvasi L, et al. Effects of one-year cyclical treatment with clodronate on postmenopausal bone loss. Bone. 1993;14:137-141.
78. Ravn P, Clemmesen B, Riis BJ, Christiansen C. The effect on bone mass and bone markers of different doses of ibandronate: a new bisphosphonate for prevention and treatment of postmenopausal osteoporosis: a 1-year, randomized, double-blind, placebo-controlled dose-finding study. Bone. 1996;19:527-533.
79. Downs RW Jr, Bell NH, Ettinger MP, et al. Comparison of alendronate and intranasal calcitonin for treatment of osteoporosis in postmenopausal women. J Clin Endocrinol Metab. 2000;85:1783-1788.
80. Rosen CJ, Bonnick SL, Miller PD, et al. Treatment of osteoporosis in postmenopausal women: alendronate vs intranasal calcitonin [abstract]. J Bone Miner Res. 1999;14(suppl 1):S400. Abstract SA365.
81. Miller PD, Woodson G, Licata AA, et al. Rechallenge of patients who had discontinued alendronate therapy because of upper gastrointestinal symptoms. Clin Ther. 2000;22:1433-1442.
82. Adachi JD, Adami S, Miller PD, et al. Tolerability of risedronate in alendronate-intolerant postmenopausal women [abstract]. Arthritis Rheum. 2000;43(suppl):S202. Abstract 815.
83. De Groen PC, Lubbe DF, Hirsch LJ, et al. Esophagitis associated with the use of alendronate. N Engl J Med. 1996;335:1016-1021.
84. Leder BZ, Kronenberg HM. Gastroenterologists and choosing the right bisphosphonate [editorial]. Gastroenterology. 2000;119:866-869.
85. Upper GI erosion rates and the bisphosphonates: more similar than different. Kirkland, Quebec: Medical Education Network, Medi News; 2001.
86. Ross PD, Santora A, Yates AJ. Epidemiology and consequences of osteoporotic fractures. In: Rosen CJ, Glowacki J, Bilezikian JP, eds. The Aging Skeleton. New York, NY: Academic Press; 1999:339-347.